Tanvex BioPharma Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '26 Mar 12, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	11,136	10,697	8,715	12,377	20,476	9,894
Market Cap Growth	-34.51%	22.75%	-29.59%	-39.55%	106.96%	-9.41%
Enterprise Value	11,289	11,603	9,691	13,133	19,692	9,494
Last Close Price	42.05	64.66	63.95	101.30	167.69	106.94
PS Ratio	49.53	308.48	141.91	552.43	3787.62	32979.06
PB Ratio	1.86	11.98	10.61	8.90	7.33	3.78
P/TBV Ratio	4.16	12.07	10.66	8.97	7.35	3.79
EV/Sales Ratio	50.21	334.59	157.80	586.21	3642.61	31645.92
Debt / Equity Ratio	0.26	1.85	2.11	1.32	0.63	0.58
Net Debt / Equity Ratio	0.03	1.42	1.65	0.76	-0.17	-0.21
Net Debt / EBITDA Ratio	-0.14	-1.01	-0.68	-0.71	0.31	0.28
Net Debt / FCF Ratio	-0.11	-1.01	-0.90	-0.74	0.33	0.30
Asset Turnover	0.04	0.01	0.02	0.01	0.00	0
Inventory Turnover	1.55	0.16	0.01	0.32	0.03	0.00
Quick Ratio	2.32	1.17	1.15	2.68	9.06	5.93
Current Ratio	2.97	1.94	1.66	3.44	9.66	6.41
Return on Equity (ROE)	-37.98%	-161.17%	-193.18%	-78.41%	-56.99%	-74.47%
Return on Assets (ROA)	-14.46%	-30.84%	-42.47%	-24.68%	-22.00%	-33.03%
Return on Capital Employed (ROCE)	-17.30%	-56.80%	-87.50%	-51.50%	-35.80%	-52.20%
Earnings Yield	-12.19%	-12.91%	-24.52%	-13.26%	-7.54%	-21.27%
FCF Yield	-12.17%	-11.75%	-17.29%	-11.53%	-6.92%	-18.74%
Buyback Yield / Dilution	-48.73%	-20.44%	-9.60%	-8.31%	-21.32%	-9.25%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.